Trials / Completed
CompletedNCT00770458
Non-Invasive Screening for Fetal Aneuploidy: A New Maternal Plasma Marker
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,000 (estimated)
- Sponsor
- Sequenom, Inc. · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Validate that circulating cell free fetal nucleic acid can be used to identify a direct marker for fetal aneuploidy, particularly fetal Down Syndrome (DS), that is better than surrogate markers.
Conditions
Timeline
- Start date
- 2008-06-01
- Primary completion
- 2009-10-01
- Completion
- 2009-12-01
- First posted
- 2008-10-10
- Last updated
- 2010-01-06
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00770458. Inclusion in this directory is not an endorsement.